Robert Schreiber
Pulmonary Disease · Great Neck, NYNPI 1992744262
Payments from drug & device makers
Across 713 payments — averaging $126.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$40K
- Mylan Specialty L.p.$19K
- Boehringer Ingelheim$17K
- Sunovion Pharmaceuticals Inc.$4K
- Regeneron Healthcare Solutions, Inc.$1K
- AstraZeneca$1K
- plus $7K from 36 others
What the payments were for
- Consulting fees$5,8506%
- Speaking & faculty fees$63,61270%
- Travel & lodging$2,5843%
- Food & beverage$17,97420%
- Education$3200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$21,402
- Yupelri$17,826
- ANORO ELLIPTA$11,373
- ANORO$4,555
- LONHALA MAGNAIR$3,645
- DUPIXENT$498
- SPiN Vision Video Processor$144
- CD HORIZON SPINAL SYSTEM$136
- UPTRAVI$125
- OPSUMIT$125
- Pulmonx Endobronchial Valve EBV$125
- OFEV$125
- LINX Reflux Management System$114
- AREXVY$114
- inCourage$113
- Arikayce$108
How this compares
$90,339 in reported general payments places this provider in the 90th percentile of 1,115 pulmonary disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $47,369 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $26,426 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $16,676 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $16,037 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,581 |
| Arnuity ElliptaFluticasone Furoate | 16 | $6,664 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $1,372 |
| Montelukast Sodium | 45 | $456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $40,463 | $86,747109 claims |
| Boehringer IngelheimStiolto Respimat | $17,463 | $26,42628 claims |
| AstraZenecaBreztri Aerosphere | $1,184 | $11,58119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Great Neck
- Jeffrey WolfGreat Neck$892K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.